drug_type
RELEVANT_DRUG
intervention_type
biologic (bispecific antibody immunotherapy)
drug_description
A bispecific T‑cell engager (BiTE) antibody construct that binds CD3 on T cells and CD19 on B‑lymphoblasts to redirect T‑cell cytotoxicity against CD19+ B‑ALL.
nci_thesaurus_concept_id
C62528
nci_thesaurus_preferred_term
Blinatumomab
nci_thesaurus_definition
A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab possesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes.
drug_mesh_term
Blinatumomab
drug_category
BISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Intravenous
drug_mechanism_of_action
Bispecific T‑cell engager that binds CD3 on T cells and CD19 on B cells, bringing them into proximity to activate TCR signaling and redirect T‑cell cytotoxicity to lyse CD19‑expressing B‑lymphoblasts.
drug_name
Blinatumomab
nct_id_drug_ref
NCT06308588